Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;15(4):285-290.
doi: 10.1007/s11901-016-0319-5. Epub 2016 Nov 5.

Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals

Yuval A Patel  1 , Andrew J Muir  1
Affiliations

Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals

Yuval A Patel et al. Curr Hepatol Rep. 2016 Dec.

Abstract

Chronic hepatitis C virus (HCV) infection is burdensome in patients with chronic kidney disease and contributes to substantial liver-related and all-cause morbidity and mortality. HCV infection itself may cause kidney dysfunction, as exemplified through mixed cryoglobulinemic vasculitis. HCV is more prevalent in patients with significant kidney disease compared to the general population, and recent reports have shown inadvertent HCV transmission in U.S. hemodialysis centers. Further, HCV has been demonstrated to accelerate kidney dysfunction and is associated with worse clinical outcomes in patients with kidney disease. As such, the HCV-infected population with concurrent kidney disease is an important patient subgroup that warrants focused medical care and attention. With the advent of direct-acting antivirals (DAAs), the successful treatment of HCV is now a medical reality for many patients. Nuances in regimen selection and timing need to be considered when treating those with kidney dysfunction, particularly for those considering kidney transplantation.

Keywords: Chronic kidney disease; Direct-acting antivirals; Hepatitis C virus.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethics Guidelines Conflict of Interest Dr. Andrew Muir reports grants and personal fees from Abbvie, grants and personal fees from BMS, grants and personal fees from Gilead, grants and personal fees from Merck, during the conduct of the study. Dr. Yuval Patel

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (Baltimore, Md) 2013;57(4):1333–42. doi: 10.1002/hep.26141. - DOI - PubMed
    1. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. American journal of nephrology. 2013;38(5):405–12. doi: 10.1159/000355615. - DOI - PubMed
    1. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. Journal of viral hepatitis. 2015;22(11):897–905. doi: 10.1111/jvh.12413. - DOI - PubMed
    1. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PloS one. 2014;9(6):e100790. doi: 10.1371/journal.pone.0100790. - DOI - PMC - PubMed
    1. Chen YC, Chiou WY, Hung SK, Su YC, Hwang SJ. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC nephrology. 2013;14:187. doi: 10.1186/1471-2369-14-187. - DOI - PMC - PubMed

LinkOut - more resources